Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | Myelofibrosis management: ruxolitinib, fedratinib, transplant

Ruben Mesa • 15 Nov 2019
MPN Advances Day 2019
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Ruxolitinib
JAKARTA JAKARTA2

Ruben Mesa, MD, FACP, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, provides an update on the management of myelofibrosis in 2019. He highlights fedratinib, which was recently approved in the US and may be making its way to Europe, as well as stem cell transplantation. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

More from Ruben Mesa

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
2:08
Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET
Ruben Mesa • 9 Dec 2023
2:26
Assessing the impact of momelotinib on transfusion burden in MF: analysis of SIMPLIFY-1 & MOMENTUM
Ruben Mesa • 9 Dec 2023
2:20
Quantifying the anemia benefit of momelotinib in MF: analysis of data from SIMPLIFY-1 & SIMPLIFY-2
Ruben Mesa • 9 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals